Open a new world for your advanced heart failure patients
Change the trajectory of Advanced Heart Failure (AHF) in your practice

Lead your AHF patients on a different course of action with HeartMate II®

You know your patients depend on you for answers throughout the disease process, whether you’ve been treating them for many years or have just diagnosed their heart condition. When medical options are no longer enough to provide meaningful benefits, take heart in knowing there is more you can do.

- Mechanical circulatory support (MCS) through a left ventricular assist device (LVAD) is the established standard of care for advanced heart failure by the American Heart Association.
- HeartMate II, the LVAD market leader, shows survival benefit 7 times that of optimal medical management alone.
- LVAD education and early identification of appropriate candidates can make the difference for you and your patients.

Understanding the life-changing potential of LVADs, the experience and benefits of HeartMate II, and how to identify appropriate patients for timely referral reflects your commitment to your advanced heart failure patients’ long-term outcomes.

Industry best practices for Advanced Heart Failure treatment

American Heart Association (AHA) guidelines identify appropriate therapeutic alternatives for each stage of heart disease

New York Heart Association (NYHA) Classification

<table>
<thead>
<tr>
<th></th>
<th>I</th>
<th>II</th>
<th>III</th>
<th>IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lifestyle changes</td>
<td>Risk factor reduction</td>
<td>Dietary restrictions</td>
<td>Palliative care (eg, inotropes)</td>
<td></td>
</tr>
<tr>
<td>Medications</td>
<td>ACE inhibitors</td>
<td>Beta-blockers</td>
<td>Dipeptidyl peptidase-IV inhibitors</td>
<td>Aldosterone antagonists</td>
</tr>
<tr>
<td>Interventional and surgical procedures</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Other than heart transplantation, an LVAD is the only option that can significantly and meaningfully improve the symptoms of AHF.

- Donor organ supply limits the availability of heart transplants; as a result, more LVADs are implanted each year than heart transplants performed.

Leading experts stress the importance of patient selection for early intervention.

- Studies demonstrate earlier referral and LVAD implantation result in shorter hospitalizations and greater survival, which may lead to lower adverse events, lower cost of care, and improved quality of life.

HeartMate II®

L exit Ventricular Assist System
Recognizing the Advanced Heart Failure patient as an LVAD patient

AHA guidelines establish LVADs as standard of care for AHF patients. Patients may be considered for an LVAD for either:
- Bridge to Transplantation (BTT), which supports patients awaiting organ donation
- Destination Therapy (DT), which supports patients ineligible for heart transplant
- Also recommended for use in a less severe patient population or in those who may elect DT

The Destination Therapy patient: A growing population

DT patients are ineligible for a heart transplant for reasons such as:
- Advanced age (ie, over 70)
- Cardiac comorbidities such as pulmonary hypertension
- Obesity
- Other serious comorbidities such as renal failure, diabetes, and recent cancer diagnosis

Patients eligible for DT fall into a particular window of health, compromised enough to require an LVAD, but otherwise healthy enough to survive and thrive through the procedure.

Only HeartMate II offers the confidence of long-term survival data

Years of clinical experience show a high percentage survival rate in both DT and BTT patients

| HeartMate II survival rates vs optimal medical management (OMM) |
|-------------|-----------------|-----------------|
| Survival (%) | 1 Year | 2 Years |
| DT: | 85% | 63% |
| BTT: | 73% | 25% |

*Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Please refer to the HeartMate II Instructions for Use about indications, contraindications, adverse events, warnings, and precautions (http://www.thoratec.com/medical-professionals/resourcelibrary/ifs-manuals/heartmate-ii-ixiv-ad.aspx).

"With heart failure, it was not a matter of if I would get worse, it was a matter of when; and when it did, my doctors pointed me in the right direction to the HeartMate II."

John
Received HeartMate II as Destination Therapy

HeartMate II®
Left Ventricular Assist System
HeartMate II delivers dramatic, sustained functional improvement

Vast majority of patients return to NYHA Class I or Class II over time2

<table>
<thead>
<tr>
<th>% of Patients Classified as NYHA Class I and Class II</th>
<th>Post HeartMate II Implant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early trial</td>
<td>Med trial</td>
</tr>
<tr>
<td>80%</td>
<td>82%</td>
</tr>
<tr>
<td>77%</td>
<td>77%</td>
</tr>
<tr>
<td>76%</td>
<td>85%</td>
</tr>
<tr>
<td>78%</td>
<td>81%</td>
</tr>
</tbody>
</table>

81% of patients experience a reversal in disease symptoms

HeartMate II offers assurance regarding complications, especially stroke

HeartMate II has the lowest published stroke rate of any continuous flow LVAD1,14,17,18

Long-term survival anchored in low stroke rates over 1,500 patient years2,14

HeartMate II Stroke Rates in Postapproval Studies

<table>
<thead>
<tr>
<th>Stroke Rates</th>
<th>BTT17</th>
<th>DT16</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Events/Patient Years]</td>
<td>2011</td>
<td>2013</td>
</tr>
<tr>
<td>N = 1,496</td>
<td>N = 247</td>
<td></td>
</tr>
<tr>
<td>1,082 Patient Years</td>
<td>385.5 Patient Years</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Type</th>
<th>BTT</th>
<th>DT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemic</td>
<td>0.06</td>
<td>0.05</td>
</tr>
<tr>
<td>Hemorrhagic</td>
<td>0.02</td>
<td>0.03</td>
</tr>
<tr>
<td>Unknown</td>
<td>0.02</td>
<td>0.0</td>
</tr>
<tr>
<td>Total</td>
<td>0.10</td>
<td>0.08</td>
</tr>
</tbody>
</table>

Take confidence in referring patients for an LVAD with HeartMate II

The most widely used and extensively studied LVAD in the world17,18

- Over 17,000 implants (as of June 2014)19
- Over 7,000 patients currently supported (as of June 2014)14
- Over 350 HeartMate II Centers in 41 countries19
- Patients are living over 10 years, and more than 400 have been going strong for more than 5 years19

*Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Please refer to the HeartMate II Instructions for Use about indications, contraindications, adverse events, warnings, and precautions (http://www.thoratec.com/medical-professionals/resource-library/ifus-manuals/heartmate-ll-lvad.aspx).

HeartMate II allows patients to get moving again11

The 6-minute walk test (6MWT) is an objective tool designed to measure activity intolerance in patients with heart failure.13

- Prior to implantation, 84% of patients could not complete the 6MWT12
- At 6 months post implantation, 94% could complete the test and walked an average of 345 meters12

“I felt like my time had really run out until I found out about the HeartMate II. I wish I’d known about it sooner.”

Aleta
Received HeartMate II as Destination Therapy
Put your patients on a path to a longer, better life: Refer them for an LVAD evaluation

The world’s leading LVAD

- Survival advantage 7 times greater than optimal medical management alone2,3
- Immediate and sustained reduction of heart failure symptoms3,*
- Dramatic and sustained improvements in functional capacity and quality of life4,*
- Lowest published stroke rate of any continuous flow LVAD11,14,15,*
- The only LVAD approved for both DT and BTT, with a proven track record in each2,10,12,14,19

References:

*Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Please refer to the HeartMate II Instructions for Use about indications, contraindications, adverse events, warnings, and precautions (http://www.thoratec.com/medical-professionals/resource-library/ifus-manuals/heartmate-ll-lvad.aspx).

www.HeartMatePro.com